about
Pathogenesis of osteoporosis: concepts, conflicts, and prospectsThe Relationship between Metabolic Syndrome and Osteoporosis: A ReviewNuclear receptors in bone physiology and diseasesBisphosphonate and risk of cancer recurrence: protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trialsNetwork Analysis Implicates Alpha-Synuclein (Snca) in the Regulation of Ovariectomy-Induced Bone LossBicc1 is a genetic determinant of osteoblastogenesis and bone mineral density.Implications of three-phase bone scintigraphy for the diagnosis of bisphosphonate-related osteonecrosis of the jawBisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk.Endogenous n-3 fatty acids protect ovariectomy induced bone loss by attenuating osteoclastogenesisOsteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database.Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trialA higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort studyAltered microRNA expression profile in exosomes during osteogenic differentiation of human bone marrow-derived mesenchymal stem cellsUse of bisphosphonates and reduced risk of colorectal cancer.Surgical treatment options in patients with impaired bone quality.Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancerBisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role.Identification of miR-194-5p as a potential biomarker for postmenopausal osteoporosis.Bisphosphonate use and the risk of endometrial cancer: a meta-analysis of observational studies.Potential role of odanacatib in the treatment of osteoporosis.A new regulator of osteoclastogenesis: estrogen response element-binding protein in bone.The Efficacy of Parathyroid Hormone Analogues in Combination With Bisphosphonates for the Treatment of Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.Statins and hip fracture prevention--a population based cohort study in womenDevelopmental origins of genotype-phenotype correlations in chronic diseases of old age.Bone densitometry. Interpretation and pitfalls.Drug insight: Existing and emerging therapies for osteoporosis.Review of postmenopausal osteoporosis pharmacotherapy.Modern treatment of thalassaemia intermedia.Fracture risk in type 2 diabetes: update of a population-based study.Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective.Bisphosphonate use and risk of colorectal cancer: a systematic review and meta-analysis.Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.Association of coronary artery and aortic calcium with lumbar bone density: the MESA Abdominal Aortic Calcium Study.Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database.Prevention of bisphosphonates-induced osteonecrosis.Updated fracture incidence rates for the US version of FRAX.A microRNA regulatory mechanism of osteoblast differentiation.Conjugated linoleic Acid prevents ovariectomy-induced bone loss in mice by modulating both osteoclastogenesis and osteoblastogenesis.Beneficial Effect of Oral Bisphosphonate Treatment on Bone Loss Induced by Chronic Administration of Furosemide without Alteration of Its Administration and Urinary Calcium Loss.
P2860
Q24536164-884CCB89-6153-4DA2-A758-73B9D1F0BD33Q26747451-0DBB0094-B8DA-48CD-9797-91126ADF7EF2Q26853017-81A9E645-C8D6-486E-8FDF-989F377DD89DQ26861586-D9D7141C-5806-4290-9842-009FACCFF607Q30276423-FB65BE10-2F39-4F85-B3D4-4E263701CA8AQ30412670-FB714C59-E898-4896-B9A8-6BB917CB6345Q33704479-4DA19031-562C-48AC-ADA1-457712654C19Q33708123-249E9125-B911-4AA9-BCE3-353E662044EEQ33793981-1D0FCF85-7765-4B04-BC86-CC5BA286D049Q34005811-5DB9B25C-C027-47FC-97FB-E31DF46E0BDAQ34375420-BBC4F93B-0559-4635-90B0-DCFEAD028676Q34541581-1A531200-A8B4-489D-8901-4F76067DBC5FQ34682095-6C8E2190-107F-485C-A766-414B2F3944EBQ34877539-DF31B8F2-F60F-4727-88E3-140D00E18703Q35078790-2F1E70C5-B2EB-4721-876F-EB43D30A40E5Q35504164-4AF7306F-2B5E-46B4-B799-F6BC92087681Q35596736-6E51F2FE-7CFE-4373-B832-FD4703C03D86Q35605709-407F672B-A65A-4A30-AB2F-FFD3A1667328Q35670992-8E7B264A-2BBA-4526-8DA5-E12AAB4E1EAEQ36097627-46053B2C-5449-4E2F-B47C-D458B31D8088Q36136239-A7A1A476-2EAE-4FD2-A632-B5A4807DD7B5Q36160358-48405D5C-1613-42A2-A2AC-E7214C17EC6AQ36255855-6B237F8F-394A-4DAE-A75E-59BC294B209FQ36353931-01BDBFE1-FFD4-4770-BF0E-9181883311C1Q36409155-FEA97A4D-EB9A-4785-94AC-839B5CCA081FQ36567710-E1C0EFA2-EB4F-4A50-AFDE-B689A46FBFCEQ36672697-1888A40E-A68C-4B5B-98EB-1BE0DDFA97E5Q36824453-A6BC2892-23A2-4935-B836-635832AB612AQ36848269-ED559C7E-4C18-4EC1-BE8C-D89297243EB0Q36952446-A48C7C10-0B1A-464A-B3D3-4E5E19782520Q37101600-02F5FC15-842E-4BA8-A668-E34FF49B1064Q37161879-FF908586-3760-4F3D-BF6C-757987B6A91CQ37174299-3101D9F2-BF11-420B-80D7-3376841BA04AQ37306185-AC535EEA-9390-4198-80A8-06F066C290A6Q37337267-4C7C5DA4-A155-4439-A34E-E737BE99AF07Q37430252-F23654DF-EA37-4604-AFE9-F6D66562B26BQ37457310-16C2B7E5-CA29-4181-89BE-454F8F09A139Q37469828-09AB45C3-847B-4A81-8C6A-91816C464DEDQ37627024-E51773AC-BEAA-449F-9A98-D68365DEEEDAQ37732700-B5CCE5D2-1469-4253-9AF7-CD08EAF3BCBA
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Clinical practice. Postmenopausal osteoporosis.
@ast
Clinical practice. Postmenopausal osteoporosis.
@en
Clinical practice. Postmenopausal osteoporosis.
@nl
type
label
Clinical practice. Postmenopausal osteoporosis.
@ast
Clinical practice. Postmenopausal osteoporosis.
@en
Clinical practice. Postmenopausal osteoporosis.
@nl
prefLabel
Clinical practice. Postmenopausal osteoporosis.
@ast
Clinical practice. Postmenopausal osteoporosis.
@en
Clinical practice. Postmenopausal osteoporosis.
@nl
P356
P1476
Clinical practice. Postmenopausal osteoporosis.
@en
P2093
Clifford J Rosen
P304
P356
10.1056/NEJMCP043801
P407
P577
2005-08-01T00:00:00Z